Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Primary Myelofibrosis 19Myeloproliferative Disorders 16Polycythemia Vera 10Leukemia 8Leukemia, Myeloid, Acute 7Breast Neoplasms 6Pancreatic Neoplasms 5Myelodysplastic Syndromes 5Hematologic Diseases 5Thrombocythemia, Essential 4Multiple Myeloma 4Bone Marrow Diseases 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasms 3Myelodysplastic-Myeloproliferative Diseases 3Leukemia, Myelomonocytic, Chronic 3Graft vs Host Disease 3Thrombocytosis 2Prostatic Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Lymphoma 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Bronchiolitis Obliterans Syndrome 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Preleukemia 1Precancerous Conditions 1Pathologic Complete Response 1

Interventions

fludarabine phosphate 31Peripheral Blood Stem Cell Transplantation 26Cyclophosphamide 25Mycophenolic Acid 24Whole-Body Irradiation 23Busulfan 21Tacrolimus 19Cyclosporine 19Antilymphocyte Serum 14Methotrexate 13Imatinib Mesylate 12Cord Blood Stem Cell Transplantation 11Melphalan 10Dasatinib 10Cyclosporins 8nilotinib 7Methylprednisolone 7Etoposide 7Radiotherapy 6Filgrastim 6Alemtuzumab 6Sirolimus 5thymoglobulin 4sargramostim 4bosutinib 4Granulocyte Colony-Stimulating Factor 4Cytarabine 4fludarabine 3Thiotepa 3Rituximab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Leukemia, Myeloid, Chronic-Phase × ruxolitinib × Clear all
NCT03654768 2025-12-18

Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia

SWOG Cancer Research Network

Phase 2 Active not recruiting
81 enrolled 20 charts
Other hematologic neoplasm

Leukemia, Myeloid, Chronic-Phase

Data powered by HemOnc (CC BY 4.0) Colophon âš¡